口腔癌治疗市场－全球产业规模、份额、趋势、机会、预测：按类型、治疗方法、分销管道、地区和竞争格局划分，2021-2031年

全球口腔癌治疗市场预计将从 2025 年的 23.8 亿美元成长到 2031 年的 32.2 亿美元，复合年增长率为 5.17%。

此领域涵盖多种旨在治疗口咽和口腔恶性肿瘤的治疗性介入，包括手术切除、放射线治疗以及免疫疗法和化疗等全身性疗法。市场成长的主要驱动力是全球口腔鳞状细胞癌发生率的上升，而口腔鳞状细胞癌的发生率上升与酒精和烟草使用量的增加以及人类乳突病毒感染的增加密切相关。此外，强调早期诊断和筛检的大规模公共卫生宣传活动正在识别出更多合格治疗条件的患者，并维持对多样化治疗方案的需求。

另一方面，新型生物製药的高成本以及开发中国家医疗基础设施的匮乏，对生物药物的广泛市场进入构成了重大障碍。这些物流和财务方面的挑战往往阻碍了先进精准医疗技术在疾病负担最重地区的推广应用。国际癌症研究机构（IARC）引用的一项2024年研究表明，仅槟榔和无烟烟草的消费就导致全球超过12万例口腔癌病例。这一数字凸显了该疾病的巨大规模，以及对价格合理且扩充性的医疗解决方案的迫切需求。

市场驱动因素

标靶治疗和免疫疗法的进步正在改变全球口腔癌治疗市场，为过去治疗选择有限的转移性或復发性口腔癌患者提供持续的治疗效果。免疫查核点抑制剂，特别是PD-1拮抗剂的出现，与传统细胞毒性疗法相比，显着提高了存活率，加速了高价值生物製药的上市。例如，2024年6月发表于ASCO的一篇文章报道，一项针对头颈癌患者的3期临床试验表明，在姑息化疗中加入低剂量Nivolumab单抗，可将一年总生存率提高至35.5%，而单纯化疗的一年总生存率为20%。这些临床成功凸显了精准医疗的有效性，并显着推动了医药投资，儘管新疗法价格昂贵，但仍能提升市场价值。

同时，全球口腔鳞状细胞癌发生率的上升是推动医疗介入需求成长的主要因素，因此亟需建立可扩展的治疗系统。吸烟仍然是主要风险因素，但由于老龄化相关风险因素以及人类乳突病毒（HPV）相关恶性肿瘤的转变，已开发地区的患者群体正在不断扩大。根据英国口腔健康基金会发布的《2024年英国口腔癌现况报告》，英国每年新增口腔癌病例达10,825例，较过去十年增加了38%。这一成长趋势凸显了在主要市场提供多样化治疗方法的迫切性。例如，美国癌症协会预测，2024年美国将新增58,450例咽癌和口腔癌病例。

市场挑战

新型生物製药的高昂成本以及开发中国家医疗基础设施的匮乏是限制全球口腔癌治疗市场成长的主要障碍。包括标靶治疗和免疫疗法在内的先进疗法价格昂贵，对于中低收入国家的支付者和患者而言往往难以负担。医疗基础设施的不足，例如缺乏诊断工具、专业的肿瘤中心以及训练有素的医护人员来管理复杂的治疗方案，进一步加剧了这一经济障碍。因此，在这些高负担地区，有很大一部分合格的患者被迫依赖疗效较差、过时的治疗方法或接受安宁疗护，从而限制了高附加价值治疗产品的潜在市场规模。

各国在资金投入和医疗政策方面的差异进一步加剧了这种医疗服务取得的困难。世界卫生组织（世卫组织）2024年的全球调查发现，只有39%的参与国将基础癌症管理纳入了其公共资助的核心医疗服务体系。这项数据凸显了阻碍口腔癌先进疗法广泛应用的严重后勤和资金不足。除非这些结构性和经济性挑战得到解决，否则创新药物生产商将难以打入新兴市场，即使全球疾病发生率不断上升，其收入成长也将受到限制。

市场趋势

人工智慧 (AI) 与治疗计划的融合正在从根本上改变全球口腔癌治疗市场，显着提升手术和放射治疗的精准度。在强度调控放射治疗(IMRT) 中，利用 AI 演算法自动勾画肿瘤和危险器官轮廓的应用日益广泛，不仅减少了人为误差和计划时间，还优化了恶性组织的剂量传递。该技术还有助于预测淋巴结转移和淋巴管外侵犯，这对于确定是否需要辅助化疗至关重要。 2025 年 7 月，《应用放射肿瘤学》杂誌报道，一种新的深度学习演算法预测这些情况的曲线下面积(AUC) 高达 0.91，显着优于传统的放射学评估，并简化了复杂头颈部恶性肿瘤的临床工作流程。

同时，液态生物检体和唾液生物标记的引入正成为非侵入性疾病监测和復发检测的主要趋势。与侵入性强且受肿瘤异质性限制的传统组织切片检查不同，液态生物检体透过分析血液和唾液中的外泌体和循环肿瘤DNA（ctDNA），提供关于治疗反应的即时资讯。这种方法能够早期识别局部復发和残留病灶，从而实现快速有效的挽救性治疗，最终提高存活率。美国国立卫生研究院于2025年4月发表的一项研究表明，复合唾液生物标记组合在区分口腔鳞状细胞癌和良性病变方面达到了88%的敏感性和80%的特异性，这表明肿瘤科医生可以製定更精准的治疗方案。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球口腔癌治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（鳞状细胞癌、疣状癌、小唾液腺癌、淋巴瘤、其他）
  • 依治疗方法（标靶治疗、化疗、免疫疗法）
  • 分销通路（医院药局、零售药局、网路药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美口腔癌治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲口腔癌治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区口腔癌治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲口腔癌治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲口腔癌治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球口腔癌治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Hospira, Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Lilly USA, LLC
• Merck & Co., Inc.
• Fresenius Kabi AG
• Accord BioPharma, Inc.
• Bristol-Myers Squibb Company
• Spectrum Pharmaceuticals, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Oral Cancer Treatment Market is projected to expand from USD 2.38 Billion in 2025 to USD 3.22 Billion by 2031, reflecting a compound annual growth rate of 5.17%. This sector encompasses a variety of therapeutic interventions, including surgical removal, radiation therapy, and systemic treatments such as immunotherapy and chemotherapy, designed to manage malignancies in the oropharynx and oral cavity. The market is primarily fueled by the rising global incidence of oral squamous cell carcinoma, which is strongly linked to high alcohol and tobacco usage, as well as the increasing prevalence of human papillomavirus infections. Additionally, broader public health campaigns emphasizing early diagnosis and screening are successfully identifying larger eligible patient groups, thereby maintaining demand for diverse therapeutic options.

Conversely, the high cost of new biological drugs and inadequate healthcare infrastructure in developing nations create significant obstacles to broad market access. These logistical and financial hurdles often prevent the adoption of advanced precision medicines in regions with the heaviest disease burden. A 2024 study cited by the International Agency for Research on Cancer noted that consumption of areca nut and smokeless tobacco alone accounted for over 120,000 oral cancer cases worldwide. This figure highlights the massive scale of the condition and the critical need for medical solutions that are both affordable and scalable.

Market Driver

Advancements in Targeted Therapies and Immunotherapy are transforming the Global Oral Cancer Treatment Market by providing lasting results for patients with metastatic or recurrent disease who previously had few alternatives. The arrival of immune checkpoint inhibitors, particularly PD-1 antagonists, has notably improved survival rates compared to traditional cytotoxic treatments, driving the uptake of high-value biological drugs. For example, ASCO Publications reported in June 2024 that a phase 3 trial adding low-dose nivolumab to palliative chemotherapy for head and neck cancer raised the one-year overall survival rate to 35.5%, compared to 20% with chemotherapy alone. Such clinical successes confirm the efficacy of precision medicine and stimulate significant pharmaceutical investment, boosting the market's value despite the high prices of new therapies.

Concurrently, the rising global prevalence of Oral Squamous Cell Carcinoma serves as a major volume driver for medical interventions, requiring scalable treatment frameworks. While tobacco use remains a leading risk factor, the patient demographic in developed regions is expanding due to age-related susceptibility and a shift toward HPV-associated malignancies. In the UK, the Oral Health Foundation's 'The State of Mouth Cancer UK Report 2024' indicated that annual diagnoses reached 10,825, a 38% increase over the last decade. This growing prevalence emphasizes the urgent need for diverse treatment modalities in key markets. Illustrating the regional impact, the American Cancer Society projected that 58,450 new cases of pharynx and oral cavity cancer would be diagnosed in the United States in 2024.

Market Challenge

The exorbitant cost of new biological medications and limited healthcare infrastructure in developing countries constitute a major barrier to the growth of the Global Oral Cancer Treatment Market. Advanced therapies, including targeted agents and immunotherapies, carry high price tags that are frequently unaffordable for payers and patients in low- and middle-income nations. This financial exclusivity is exacerbated by insufficient medical infrastructure, which lacks the necessary diagnostic tools, specialized oncology centers, and trained staff needed to manage complex treatment regimens. Consequently, a large portion of the eligible patient population in these high-burden regions relies on less effective, older modalities or receives palliative care, restricting the total addressable market for premium therapeutic products.

This lack of access is further underscored by gaps in national funding and health policies. A 2024 global survey by the World Health Organization revealed that only 39% of participating countries included basic cancer management in their funded core health services. This statistic points to severe logistical and financial deficits that hinder the widespread adoption of advanced oral cancer treatments. As long as these structural and economic inadequacies remain, manufacturers of innovative drugs will struggle to penetrate emerging markets, limiting revenue growth despite the increasing global incidence of the disease.

Market Trends

The Integration of Artificial Intelligence in Treatment Planning is fundamentally altering the Global Oral Cancer Treatment Market by improving the accuracy of surgical and radiation procedures. AI algorithms are increasingly utilized to automate the contouring of tumors and at-risk organs during Intensity-Modulated Radiation Therapy (IMRT), reducing human error and planning time while optimizing dose delivery to malignant tissues. This technology also helps predict nodal metastasis and extranodal extension, which are crucial for determining the need for adjuvant chemotherapy. In July 2025, Applied Radiation Oncology reported that a new deep-learning algorithm predicted these conditions with an Area Under the Curve (AUC) of 0.91, significantly outperforming traditional radiological assessments and streamlining clinical workflows for complex head and neck malignancies.

Simultaneously, the Implementation of Liquid Biopsy and Salivary Biomarkers is becoming a key trend for non-invasive disease monitoring and recurrence detection. Unlike standard tissue biopsies, which are invasive and limited by tumor heterogeneity, liquid biopsies analyze exosomes and circulating tumor DNA (ctDNA) in blood or saliva to provide real-time insights into treatment response. This method allows for the early identification of local recurrence and residual disease, facilitating timely salvage interventions that can improve survival rates. A study published by the National Institutes of Health in April 2025 showed that a combined salivary biomarker panel achieved 88% sensitivity and 80% specificity in distinguishing oral squamous cell carcinoma from benign lesions, enabling oncologists to tailor management plans with greater precision.

Key Market Players

• Novartis AG
• Hospira, Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Lilly USA, LLC
• Merck & Co., Inc.
• Fresenius Kabi AG
• Accord BioPharma, Inc.
• Bristol-Myers Squibb Company
• Spectrum Pharmaceuticals, Inc

Report Scope

In this report, the Global Oral Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Cancer Treatment Market, By Type

• Squamous Cell Carcinoma
• Verrucous Carcinoma
• Minor Salivary Gland Carcinomas
• Lymphomas
• others

Oral Cancer Treatment Market, By Treatment

• Targeted Therapy
• Chemotherapy
• Immunotherapy

Oral Cancer Treatment Market, By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

Oral Cancer Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Cancer Treatment Market.

Available Customizations:

Global Oral Cancer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Cancer Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Squamous Cell Carcinoma, Verrucous Carcinoma, Minor Salivary Gland Carcinomas, Lymphomas, others)
  • 5.2.2. By Treatment (Targeted Therapy, Chemotherapy, Immunotherapy)
  • 5.2.3. By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Oral Cancer Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Cancer Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Oral Cancer Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Oral Cancer Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Oral Cancer Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oral Cancer Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Oral Cancer Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Oral Cancer Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Oral Cancer Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Oral Cancer Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Oral Cancer Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oral Cancer Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Oral Cancer Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Oral Cancer Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Oral Cancer Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Oral Cancer Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Oral Cancer Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oral Cancer Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Oral Cancer Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Oral Cancer Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. South America Oral Cancer Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oral Cancer Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Oral Cancer Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Oral Cancer Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oral Cancer Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Hospira, Inc.
• 15.3. Teva Pharmaceutical Industries Ltd
• 15.4. Pfizer Inc.
• 15.5. Lilly USA, LLC
• 15.6. Merck & Co., Inc.
• 15.7. Fresenius Kabi AG
• 15.8. Accord BioPharma, Inc.
• 15.9. Bristol-Myers Squibb Company
• 15.10. Spectrum Pharmaceuticals, Inc

16. Strategic Recommendations

17. About Us & Disclaimer